CTRI/2022/06/043305尚未招募3 期
Evaluation of efficacy and tolerability of select Ayurveda formulations in moderate Iron Deficiency Anemia â?? A randomized controlled trial
Central Council for Research In Ayurvedic Sciences CCRASMinistry Of Ayush Govt Of India0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •i. Participants of age between 18 to 55 years of any sex.
- •ii. Hemoglobin ranging between 8 to 10.9 gm/dl
- •iii. Hematocrit less than 41% in men and less than 36% in women
- •iv. Mean corpuscular volume less than 80%
- •v. Willing to provide informed written consent for participation in study
排除标准
- •i.Recent history of severe acute or chronic blood loss from the gastro intestinal or other sources in the form of Haematemesis, Melena, Bleeding Piles, Hemoptysis, Menorrhagia, surgery, trauma, etc.
- •ii.Participants suffering from megaloblastic anemia (pernicious anemia) (Serum Vit. B12 <150 pg/ml) or Hypothyroidism (TSH >10 mIU/L)
- •iii.Patients already on iron supplements at present or during the last 3 months
- •iv.Known case of disease conditions with intestinal malabsorption, alcohol use disorder (AUD) (CAGE score >2), anaemia due to chronic disease and medications, Thalassemia, Sideroblastic anemia, sickle cell, cold hemoglobinuria (Donath-Landsteiner hemolytic anemia), cold agglutinin disease (cold antibody hemolytic anemia), and other hemolytic anemias disseminated intravascular coagulation (DIC), Bone marrow suppression (aplastic anemia and myelophthisic anemia), Myelodysplastic syndromes, mechanical heart valves, hemolytic uremic syndrome (HUS), etc.
- •v. Known case of other major co-morbidities like chronic cardiac/ pulmonary diseases, malignancy, etc.
- •vi.Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2mg/dl)
- •vii.Patients on prolonged ( > 6 weeks) medication (steroids, immune-suppressants, disease modifying agents, chemotherapy etc.) for any chronic disease that may have an influence on the outcome of the study
- •viii. Pregnant women or women who are planning for conception or lactating mothers
研究者
相似试验
已完成
3 期
Evaluation of efficacy and tolerability of select Ayurveda formulations in moderate Iron Deficiency AnemiaCTRI/2022/06/043097Ministry of Tribal Affairs240
进行中（未招募）
1 期
Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placeboEfficacy and tolerability investigations of a healing water in symptomatic treatment of heartburnMedDRA version: 20.0Level: LLTClassification code 10019326Term: HeartburnSystem Organ Class: 100000004856EUCTR2017-001100-30-DEFachingen Heil- und Mineralbrunnen GmbH150
招募中
3 期
Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placeboMedDRA - Heartburn 10019326R12HeartburnDRKS00016696Fachingen Heil- und Mineralbrunnen GmbH150
进行中（未招募）
1 期
Imiquimod versus PDT for actinic keratoses in in organ transplant recipientsEUCTR2012-000263-24-ATMedizinische Universität Wien, Univ. Klinik f. Dermatologie30
进行中（未招募）
不适用
Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCEMULTIPLE SCLEROSISEUCTR2005-006071-12-ITAZIENDA OSPEDALIERA SAN CAMILLO FORLANINI276